Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia.
Zozulia AA, Neznamov GG, Siuniakov TS, et al. · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova
Open clinical investigation reported anxiolytic efficacy of intranasal Selank in patients with generalized anxiety disorder and neurasthenia, with a tolerability profile distinct from benzodiazepines.
Investigated as a clinical (GAD and neurasthenia patients) in the field of neuroscience research. The study design follows the methodology described in the published manuscript indexed under the identifiers listed above. Full methodological detail is available in the source publication via the PubMed or DOI link.
Open clinical investigation reported anxiolytic efficacy of intranasal Selank in patients with generalized anxiety disorder and neurasthenia, with a tolerability profile distinct from benzodiazepines.
Russian-language publication with limited blinding/control design; results have not been replicated in large international randomized trials.
- · PubMed: PMID 18454096 ↗
- · PubMed search by title: pubmed.ncbi.nlm.nih.gov ↗
- · Google Scholar: scholar.google.com ↗